Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine

详细信息    查看全文

• 作者：Ali Rowhani-Rahbar^a ; ^b ; ^{ali.x.rowhani-rahbar@kp.org} ; Frances B. Alvarez^c ; Janine T. Bryan^c ; ^d ; James P. Hughes^e ; Stephen E. Hawes^a ; Noel S. Weiss^a ; Laura A. Koutsky^a
• 关键词：RCT ; randomized controlled trial ; HPV ; human papillomavirus ; VLP ; virus-like particle ; GMT ; geometric mean titer ; MRL ; Merck Research Laboratories ; cLIA ; competitive Luminex immunoassay ; CI ; confidence interval
• 刊名：Journal of Clinical Virology
• 出版年：2012
• 出版时间：March 2012
• 年：2012
• 卷：53
• 期：3
• 页码：239-243
• 全文大小：488 K

文摘

Background

The duration of protection conferred by prophylactic human papillomavirus (HPV) L1 virus-like particle vaccines is a critical determinant of their public health impact. A feature of vaccines that confer long-term immunity is their ability to induce immune memory.

Objectives

We evaluated antibody responses against HPV types 6, 11, 16 and 18 following administration of the quadrivalent HPV-6/11/16/18 vaccine to women who had previously received a monovalent HPV-16 vaccine.

Study design

As part of an extended follow-up study conducted between 2006 and 2009 in Seattle, Washington, we administered the quadrivalent HPV-6/11/16/18 vaccine to 52 women (19 vaccine and 33 placebo recipients) who had participated in a monovalent HPV-16 vaccine trial 8.5 years earlier. Serum samples were tested for anti-HPV antibodies using competitive Luminex immunoassay.

Results

Following administration of the first dose of the quadrivalent HPV-6/11/16/18 vaccine, the anti-HPV-16 geometric mean titer among monovalent HPV-16 vaccine recipients (GMT = 5024.0 milli-Merck units per milliliter [mMU/mL]; 95 % confidence interval [CI]: 2710.1, 9313.6 mMU/mL) substantially exceeded that among the placebo recipients (GMT = 136.1; 95 % CI: 78.5, 235.8 mMU/mL; p < 0.01) and their own highest anti-HPV-16 response observed during the original trial (GMT at month 7 of the original trial = 1552.7 mMU/mL; 95 % CI: 1072.6, 2247.7 mMU/mL; p < 0.01).

Conclusions

The findings suggest that the administration of the three-dose regimen of the monovalent HPV-16 vaccine had produced memory lymphocytes, characterized by a heightened immune response following administration of the quadrivalent HPV-6/11/16/18 vaccine that effectively served as an antigen challenge.